Li Li, Li Lu, Wu Yan, Gao Xing-Hua, Chen Hong-Duo
a Department of Dermatology , The First Hospital of China Medical University , Shenyang , China.
b Department of Dermatology , No. 3 Hospital of Xi'an City, Xi'an , China.
J Cosmet Laser Ther. 2016 Jun;18(3):182-5. doi: 10.3109/14764172.2015.1114646. Epub 2016 Mar 8.
Vitiligo is an acquired depigmenting disease with uncertain etiopathogenesis and the treatment modalities need to be consistently updated.
To evaluate a triple-combination treatment with oral α-lipoic acid (ALA), betamethasone injection, and narrowband ultraviolet B (NB-UVB) on vitiligo.
Patients with non-segmental and progressive vitiligo lesions were randomly assigned to two groups. The treatment group and the control group were respectively treated with oral ALA and placebo, in combination with betamethasone injection and NB-UVB. The effectiveness and adverse events were evaluated by investigators and patients before and after treatment.
Fifty non-segmental progressive vitiligo patients were enrolled in the study. The treatment period was 6 months. In treatment group, over 40% patients achieved > 50% improvement and ≥ 5 satisfaction score by 3-month therapy (M3). This percentage increased to 90% at M6. Treatment group achieved better efficacy than control group at M3, while no difference was seen at M6.
The combined treatment with oral ALA, betamethasone injection, and NB-UVB was effective and safe on non-segmental progressive vitiligo. ALA could accelerate the initial response of repigmentation.
白癜风是一种病因不明的获得性色素脱失性疾病，治疗方式需要不断更新。
评估口服α-硫辛酸（ALA）、倍他米松注射和窄谱中波紫外线（NB-UVB）三联疗法治疗白癜风的效果。
将非节段性进展期白癜风患者随机分为两组。治疗组和对照组分别口服ALA和安慰剂，并联合倍他米松注射及NB-UVB治疗。由研究者和患者在治疗前后评估疗效及不良事件。
50例非节段性进展期白癜风患者纳入本研究。治疗周期为6个月。治疗组中，超过40%的患者在治疗3个月（M3）时色素恢复改善>50%且满意度评分≥5分。该比例在M6时增至90%。治疗组在M3时疗效优于对照组，而在M6时未见差异。
口服ALA、倍他米松注射和NB-UVB联合治疗非节段性进展期白癜风有效且安全。ALA可加速色素恢复的初始反应。
